{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T17:28:37Z","timestamp":1793381317995,"version":"4.5.0"},"reference-count":283,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2024,1,4]],"date-time":"2024-01-04T00:00:00Z","timestamp":1704326400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Psoriasis is a chronic autoimmune inflammatory disease characterized by erroneous metabolism of keratinocytes. The development of psoriasis is closely related to abnormal activation and disorders of the immune system. Dysregulated skin protective mechanisms can activate inflammatory pathways within the epithelial immune microenvironment (EIME), leading to the development of autoimmune-related and inflammatory skin diseases. In this review, we initially emphasized the pathogenesis of psoriasis, paying particular attention to the interactions between the abnormal activation of immune cells and the production of cytokines in psoriasis. Subsequently, we delved into the significance of the interactions between EIME and immune cells in the emergence of psoriasis. A thorough understanding of these immune processes is crucial to the development of targeted therapies for psoriasis. Finally, we discussed the potential novel targeted therapies aimed at modulating the EIME in psoriasis. This comprehensive examination sheds light on the intricate underlying immune mechanisms and provides insights into potential therapeutic avenues of immune-mediated inflammatory diseases.<\/jats:p>","DOI":"10.3389\/fimmu.2023.1340677","type":"journal-article","created":{"date-parts":[[2024,1,4]],"date-time":"2024-01-04T05:06:31Z","timestamp":1704344791000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":42,"title":["Immune cells in the epithelial immune microenvironment of psoriasis: emerging therapeutic targets"],"prefix":"10.3389","volume":"14","author":[{"given":"Lisha","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaye","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junchao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyue","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiying","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zongguang","family":"Tai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quangang","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongjian","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2024,1,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"ii18","DOI":"10.1136\/ard.2004.033217","article-title":"Psoriasis: epidemiology, clinical features, and quality of life","author":"Langley","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"B2","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1111\/jdv.18044","article-title":"Psoriasis and metabolic syndrome: implications for the management and treatment of psoriasis","volume":"36","author":"Wu","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19341","article-title":"Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): results from a phase III, randomized, open-label, efficacy-assessor-blinded clinical trial","volume":"184","author":"Warren","year":"2021","journal-title":"Br J Dermatol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2022.07.016","article-title":"Macrophages as a therapeutic target to promote diabetic wound healing","volume":"30","author":"Sharifiaghdam","year":"2022","journal-title":"Mol Ther"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-016-8535-x","article-title":"The inflammatory response in psoriasis: a comprehensive review","volume":"50","author":"Deng","year":"2016","journal-title":"Clin Rev Allergy Immunol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.21627","article-title":"Biomarkers of disease progression in people with psoriasis: a scoping review","volume":"187","author":"Ramessur","year":"2022","journal-title":"Br J Dermatol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.14663","article-title":"Roflumilast for chronic plaque psoriasis","volume":"328","author":"Cordoro","year":"2022","journal-title":"JAMA"},{"key":"B8","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1136\/annrheumdis-2021-219961","article-title":"Biological disease-modifying antirheumatic drugs may mitigate the risk of psoriatic arthritis in patients with chronic plaque psoriasis","volume":"81","author":"Gisondi","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.2174\/138161211798157649","article-title":"A pathogenetic approach to autoimmune skin disease therapy: psoriasis and biological drugs, unresolved issues, and future directions","volume":"17","author":"Ayroldi","year":"2011","journal-title":"Curr Pharm Des"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61128-3","article-title":"Pathogenesis and clinical features of psoriasis","volume":"370","author":"Griffiths","year":"2007","journal-title":"Lancet"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1021\/acsami.3c00058","article-title":"Supramolecular dissolving microneedle patch loading hydrophobic glucocorticoid for effective psoriasis treatment","volume":"15","author":"Wang","year":"2023","journal-title":"ACS Appl Mater Interfaces"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.17113","article-title":"Long-term safety and efficacy of a fixed-combination halobetasol propionate 0.01%\/tazarotene 0.045% lotion in moderate-to-severe plaque psoriasis: phase 3 open-label study","volume":"35","author":"Lebwohl","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.jaad.2019.08.049","article-title":"Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis in pediatric patients","volume":"82","author":"Menter","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/0190-9622(93)70283-y","article-title":"PUVA, UVB, psoriasis, and nonmelanoma skin cancer","volume":"29","author":"Studniberg","year":"1993","journal-title":"J Am Acad Dermatol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)32549-6","article-title":"Psoriasis","volume":"397","author":"Griffiths","year":"2021","journal-title":"Lancet"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.825032","article-title":"C10orf99\/GPR15L regulates proinflammatory response of keratinocytes and barrier formation of the skin","volume":"13","author":"Dainichi","year":"2022","journal-title":"Front Immunol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/s41419-022-04523-3","article-title":"Advances in the pathogenesis of psoriasis: from keratinocyte perspective","volume":"13","author":"Zhou","year":"2022","journal-title":"Cell Death Dis"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00184-7","article-title":"Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis","volume":"397","author":"Ghoreschi","year":"2021","journal-title":"Lancet"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-018-0256-2","article-title":"The epithelial immune microenvironment (EIME) in atopic dermatitis and psoriasis","volume":"19","author":"Dainichi","year":"2018","journal-title":"Nat Immunol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1172\/JCI97426","article-title":"MicroRNA-210 overexpression promotes psoriasis-like inflammation by inducing Th1 and Th17 cell differentiation","volume":"128","author":"Wu","year":"2018","journal-title":"J Clin Invest"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2015.08.015","article-title":"The Asian atopic dermatitis phenotype combines features of atopic dermatitis and psoriasis with increased TH17 polarization","volume":"136","author":"Noda","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2017.07.004","article-title":"Psoriasis pathogenesis and the development of novel targeted immune therapies","volume":"140","author":"Hawkes","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1038\/s41392-021-00658-5","article-title":"Inflammation and tumor progression: signaling pathways and targeted intervention","volume":"6","author":"Zhao","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1475","DOI":"10.3390\/ijms20061475","article-title":"Psoriasis pathogenesis and treatment","volume":"20","author":"Rendon","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1980.tb05690.x","article-title":"Psoriasis and HLA-cw6","volume":"102","author":"Tiilikainen","year":"1980","journal-title":"Br J Dermatol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16083","article-title":"HLA-cw6 and psoriasis","volume":"178","author":"Chen","year":"2018","journal-title":"Br J Dermatol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-020-00585-1","article-title":"HLA-cw1 and psoriasis","volume":"22","author":"Huang","year":"2021","journal-title":"Am J Clin Dermatol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20151093","article-title":"Melanocyte antigen triggers autoimmunity in human psoriasis","volume":"212","author":"Arakawa","year":"2015","journal-title":"J Exp Med"},{"key":"B29","doi-asserted-by":"publisher","first-page":"7488","DOI":"10.3390\/ijms21207488","article-title":"New Treatment Addressing the Pathogenesis of Psoriasis, International journal of molecular sciences","volume":"21","author":"Tokuyama","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcdb.2021.06.018","article-title":"Keratin 17 in psoriasis: Current understanding and future perspectives","volume":"128","author":"Lin","year":"2022","journal-title":"Semin Cell Dev Biol"},{"key":"B31","doi-asserted-by":"publisher","first-page":"807","DOI":"10.3390\/cells8080807","article-title":"Keratin 6, 16 and 17-critical barrier alarmin molecules in skin wounds and psoriasis","volume":"8","author":"Zhang","year":"2019","journal-title":"Cells"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1002\/path.5178","article-title":"Keratin 17 in disease pathogenesis: from cancer to dermatoses","volume":"247","author":"Yang","year":"2019","journal-title":"J Pathol"},{"key":"B33","doi-asserted-by":"publisher","first-page":"4347","DOI":"10.3390\/ijms20184347","article-title":"Risk Factors for the Development of Psoriasis, International journal of molecular sciences","volume":"20","author":"Kamiya","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01525","article-title":"The role of epigenetics in autoimmune\/inflammatory disease","volume":"10","author":"Surace","year":"2019","journal-title":"Front Immunol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jaut.2016.12.002","article-title":"Epigenetics of psoriatic disease: A systematic review and critical appraisal","volume":"78","author":"Pollock","year":"2017","journal-title":"J Autoimmun"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-022-08956-8","article-title":"Epigenetic dysregulation in autoimmune and inflammatory skin diseases","volume":"63","author":"Gibson","year":"2022","journal-title":"Clin Rev Allergy Immunol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3794","article-title":"Targeting IL-17 and TH17 cells in chronic inflammation, Nature reviews","volume":"11","author":"Miossec","year":"2012","journal-title":"Drug Discovery"},{"key":"B38","doi-asserted-by":"publisher","first-page":"102429","DOI":"10.1016\/j.autrev.2019.102429","article-title":"Critical role of interleukin (IL)-17 in inflammatory and immune disorders: An updated review of the evidence focusing in controversies","volume":"19","author":"Ruiz de Morales","year":"2020","journal-title":"Autoimmun Rev"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-018-8702-3","article-title":"The immunologic role of IL-17 in psoriasis and psoriatic arthritis pathogenesis","volume":"55","author":"Blauvelt","year":"2018","journal-title":"Clin Rev Allergy Immunol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-04-325225","article-title":"Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey","volume":"119","author":"Aggarwal","year":"2012","journal-title":"Blood"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217163","article-title":"Pharmacological treatment of psoriatic arthritis: a systematic literature research for the 2019 update of the EULAR recommendations for the management of psoriatic arthritis","volume":"79","author":"Kerschbaumer","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2015.01.011","article-title":"Guidance for the management of patients with latent tuberculosis infection requiring biologic therapy in rheumatology and dermatology clinical practice","volume":"14","author":"Cantini","year":"2015","journal-title":"Autoimmun Rev"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2014.106","article-title":"Advances in the management of psoriatic arthritis","volume":"10","author":"Olivieri","year":"2014","journal-title":"Nat Rev Rheumatol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/bjd.12937","article-title":"Early tissue responses in psoriasis to the antitumour necrosis factor-alpha biologic etanercept suggest reduced interleukin-17 receptor expression and signalling","volume":"171","author":"Johnston","year":"2014","journal-title":"Br J Dermatol"},{"key":"B45","doi-asserted-by":"publisher","first-page":"12793","DOI":"10.3390\/ijms222312793","article-title":"The Cytokine Mediated Molecular Pathophysiology of Psoriasis and Its Clinical Implications, International journal of molecular sciences","volume":"22","author":"Singh","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B46","doi-asserted-by":"publisher","first-page":"2656","DOI":"10.1016\/j.jid.2021.04.018","article-title":"Cyclin-dependent kinase 7 promotes th17\/th1 cell differentiation in psoriasis by modulating glycolytic metabolism","volume":"141","author":"Lin","year":"2021","journal-title":"J Invest Dermatol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keac385","article-title":"IL-17A and TNF synergistically drive expression of proinflammatory mediators in synovial fibroblasts via IkappaBzeta-dependent induction of ELF3","volume":"62","author":"Kouri","year":"2023","journal-title":"Rheumatol (Oxford)"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abd1287","article-title":"The m(6)A reader IMP2 directs autoimmune inflammation through an IL-17- and TNFalpha-dependent C\/EBP transcription factor axis","volume":"6","author":"Bechara","year":"2021","journal-title":"Sci Immunol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/jid.2012.194","article-title":"The emerging role of IL-17 in the pathogenesis of psoriasis: preclinical and clinical findings","volume":"133","author":"Martin","year":"2013","journal-title":"J Invest Dermatol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/j.jaci.2009.08.046","article-title":"Effective treatment of psoriasis with etanercept is linked to suppression of IL-17 signaling, not immediate response TNF genes","volume":"124","author":"Zaba","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41577-022-00746-9","article-title":"IL-17 and IL-17-producing cells in protection versus pathology","volume":"23","author":"Mills","year":"2023","journal-title":"Nat Rev Immunol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-020-00578-0","article-title":"Use of IL-23 inhibitors for the treatment of plaque psoriasis and psoriatic arthritis: A comprehensive review","volume":"22","author":"Yang","year":"2021","journal-title":"Am J Clin Dermatol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.ajpath.2012.03.044","article-title":"Th17 cells: biology, pathogenesis of autoimmune and inflammatory diseases, and therapeutic strategies","volume":"181","author":"Maddur","year":"2012","journal-title":"Am J Pathol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-019-0467-1","article-title":"IL-1R3 blockade broadly attenuates the functions of six members of the IL-1 family, revealing their contribution to models of disease","volume":"20","author":"Hojen","year":"2019","journal-title":"Nat Immunol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"154384","DOI":"10.1016\/j.phymed.2022.154384","article-title":"Combining network pharmacology, RNA-seq, and metabolomics strategies to reveal the mechanism of Cimicifugae Rhizoma - Smilax glabra Roxb herb pair for the treatment of psoriasis","volume":"105","author":"Hu","year":"2022","journal-title":"Phytomedicine"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-202264","article-title":"The novel cytokine interleukin-36alpha is expressed in psoriatic and rheumatoid arthritis synovium","volume":"72","author":"Frey","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19795","article-title":"Activity and components of the granulocyte colony-stimulating factor pathway in hidradenitis suppurativa","volume":"185","author":"Wolk","year":"2021","journal-title":"Br J Dermatol"},{"key":"B58","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.cytogfr.2018.01.001","article-title":"The enigmatic role of IL-38 in inflammatory diseases","volume":"39","author":"Garraud","year":"2018","journal-title":"Cytokine Growth Factor Rev"},{"key":"B59","doi-asserted-by":"publisher","first-page":"216224","DOI":"10.1016\/j.canlet.2023.216224","article-title":"PDE4D\/cAMP\/IL-23 axis determines the immunotherapy efficacy of lung adenocarcinoma via activating the IL-9 autocrine loop of cytotoxic T lymphocytes","volume":"565","author":"Feng","year":"2023","journal-title":"Cancer Lett"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1038\/ni.3347","article-title":"Epigenetic regulation of the expression of Il12 and Il23 and autoimmune inflammation by the deubiquitinase Trabid","volume":"17","author":"Jin","year":"2016","journal-title":"Nat Immunol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-022-01339-3","article-title":"IL-17D-induced inhibition of DDX5 expression in keratinocytes amplifies IL-36R-mediated skin inflammation","volume":"23","author":"Ni","year":"2022","journal-title":"Nat Immunol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1038\/nature07021","article-title":"IL-21 and TGF-beta are required for differentiation of human T(H)17 cells","volume":"454","author":"Yang","year":"2008","journal-title":"Nature"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2006.01.001","article-title":"TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells","volume":"24","author":"Veldhoen","year":"2006","journal-title":"Immunity"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1038\/ni.1698","article-title":"The interleukin 23 receptor is essential for the terminal differentiation of interleukin 17-producing effector T helper cells in vivo","volume":"10","author":"McGeachy","year":"2009","journal-title":"Nat Immunol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1038\/ni1391","article-title":"Signals mediated by transforming growth factor-beta initiate autoimmune encephalomyelitis, but chronic inflammation is needed to sustain disease","volume":"7","author":"Veldhoen","year":"2006","journal-title":"Nat Immunol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.732790","article-title":"The pathological mechanism and potential application of IL-38 in autoimmune diseases","volume":"12","author":"Han","year":"2021","journal-title":"Front Pharmacol"},{"key":"B67","doi-asserted-by":"publisher","first-page":"3222","DOI":"10.1016\/j.jid.2022.06.021","article-title":"Functional interplay between IL-9 and peptide YY contributes to chronic skin inflammation","volume":"142","author":"Kamiya","year":"2022","journal-title":"J Invest Dermatol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.168.11.5699","article-title":"A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rbeta1 and a novel cytokine receptor subunit","volume":"168","author":"Parham","year":"2002","journal-title":"IL-23R J Immunol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1111\/j.0105-2896.2004.00211.x","article-title":"Signaling by IL-12 and IL-23 and the immunoregulatory roles of STAT4","volume":"202","author":"Watford","year":"2004","journal-title":"Immunol Rev"},{"key":"B70","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/s41577-018-0084-5","article-title":"The immunological anatomy of the skin","volume":"19","author":"Kabashima","year":"2019","journal-title":"Nat Rev Immunol"},{"key":"B71","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.cytogfr.2019.01.001","article-title":"Emerging role of immune cell network in autoimmune skin disorders: An update on pemphigus, vitiligo and psoriasis","volume":"45","author":"Das","year":"2019","journal-title":"Cytokine Growth Factor Rev"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1038\/ni.3726","article-title":"IL-17(+) gammadelta T cells as kick-starters of inflammation","volume":"18","author":"Papotto","year":"2017","journal-title":"Nat Immunol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1038\/nri2622","article-title":"Skin immune sentinels in health and disease","volume":"9","author":"Nestle","year":"2009","journal-title":"Nat Rev Immunol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01234","article-title":"Potential immunological links between psoriasis and cardiovascular disease","volume":"9","author":"Sajja","year":"2018","journal-title":"Front Immunol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2017.07.011","article-title":"Autoimmune aspects of psoriasis: Heritability and autoantigens","volume":"16","author":"Prinz","year":"2017","journal-title":"Autoimmun Rev"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00954","article-title":"Human leukocyte antigen-class I alleles and the autoreactive T cell response in psoriasis pathogenesis","volume":"9","author":"Prinz","year":"2018","journal-title":"Front Immunol"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1800013","article-title":"Discovery of the IL-23\/IL-17 signaling pathway and the treatment of psoriasis","volume":"201","author":"Hawkes","year":"2018","journal-title":"J Immunol"},{"key":"B78","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1056\/NEJMra0804595","article-title":"Psoriasis","volume":"361","author":"Nestle","year":"2009","journal-title":"N Engl J Med"},{"key":"B79","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1146\/annurev-pathol-011811-132448","article-title":"Psoriasis","volume":"7","author":"Perera","year":"2012","journal-title":"Annu Rev Pathol"},{"key":"B80","doi-asserted-by":"publisher","first-page":"16082","DOI":"10.1038\/nrdp.2016.82","article-title":"Psoriasis, nature reviews","volume":"2","author":"Greb","year":"2016","journal-title":"Dis Primers"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-101819-025146","article-title":"Dendritic cell regulation of T helper cells","volume":"39","author":"Yin","year":"2021","journal-title":"Annu Rev Immunol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.add4132","article-title":"pDC-like cells are pre-DC2 and require KLF4 to control homeostatic CD4 T cells","volume":"8","author":"Rodrigues","year":"2023","journal-title":"Sci Immunol"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-004400","article-title":"PD-L1 blockade restores CAR T cell activity through IFN-gamma-regulation of CD163+ M2 macrophages","volume":"10","author":"Yamaguchi","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1006\/smim.1994.1032","article-title":"CD4\/CD8 lineage commitment in T cell receptor transgenic mice: evidence for precommitment of CD4+ CD8+ thymocytes","volume":"6","author":"Crompton","year":"1994","journal-title":"Semin Immunol"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2009.399","article-title":"Circulating Th17, Th22, and Th1 cells are increased in psoriasis","volume":"130","author":"Kagami","year":"2010","journal-title":"J Invest Dermatol"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1038\/nature05663","article-title":"Pathogenesis and therapy of psoriasis","volume":"445","author":"Lowes","year":"2007","journal-title":"Nature"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2021.08.002","article-title":"Tissue-specific differentiation of CD8(+) resident memory T cells","volume":"42","author":"Yang","year":"2021","journal-title":"Trends Immunol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2020.11.028","article-title":"Single-cell RNA sequencing of psoriatic skin identifies pathogenic Tc17 cell subsets and reveals distinctions between CD8(+) T cells in autoimmunity and cancer","volume":"147","author":"Liu","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2014.08.010","article-title":"Classification of inflammatory skin diseases: a proposal based on the disorders of the three-layered defense systems, barrier, innate immunity and acquired immunity","volume":"76","author":"Dainichi","year":"2014","journal-title":"J Dermatol Sci"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000000895","article-title":"Contribution of keratinocytes to dermal fibrosis","volume":"34","author":"Russo","year":"2022","journal-title":"Curr Opin Rheumatol"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1016\/j.ceb.2020.09.004","article-title":"Advances in resolving the heterogeneity and dynamics of keratinocyte differentiation","volume":"67","author":"Rice","year":"2020","journal-title":"Curr Opin Cell Biol"},{"key":"B92","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.it.2020.11.005","article-title":"Targeting Skin-Resident Memory T Cells via Vaccination to Combat Staphylococcus aureus Infections","volume":"42","author":"Clegg","year":"2021","journal-title":"Trends Immunol"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1038\/nri3683","article-title":"The origins and functions of dendritic cells and macrophages in the skin","volume":"14","author":"Malissen","year":"2014","journal-title":"Nat Rev Immunol"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.929000","article-title":"The dendritic cell dilemma in the skin: between tolerance and immunity","volume":"13","author":"Scheib","year":"2022","journal-title":"Front Immunol"},{"key":"B95","doi-asserted-by":"publisher","first-page":"2953","DOI":"10.3390\/cells11192953","article-title":"Macrophage-mediated inflammation in skin wound healing","volume":"11","author":"Hassanshahi","year":"2022","journal-title":"Cells"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2019.05.001","article-title":"The healing power of neutrophils","volume":"40","author":"Phillipson","year":"2019","journal-title":"Trends Immunol"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1126\/science.abe7729","article-title":"Neutrophils self-limit swarming to contain bacterial growth in vivo","volume":"372","author":"Kienle","year":"2021","journal-title":"Science"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1096\/fj.201900642R","article-title":"Keratinocyte exosomes activate neutrophils and enhance skin inflammation in psoriasis","volume":"33","author":"Jiang","year":"2019","journal-title":"FASEB J"},{"key":"B99","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1038\/s41577-019-0162-3","article-title":"T cells and the skin: from protective immunity to inflammatory skin disorders","volume":"19","author":"Ho","year":"2019","journal-title":"Nat Rev Immunol"},{"key":"B100","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1038\/s41423-019-0291-4","article-title":"Tissue-resident memory T cells and their biological characteristics in the recurrence of inflammatory skin disorders","volume":"17","author":"Chen","year":"2020","journal-title":"Cell Mol Immunol"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1186455","article-title":"Revisiting the interleukin 17 family of cytokines in psoriasis: pathogenesis and potential targets for innovative therapies","volume":"14","author":"Brembilla","year":"2023","journal-title":"Front Immunol"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-022-00940-8","article-title":"The epidermal immune microenvironment plays a dominant role in psoriasis development, as revealed by mass cytometry","volume":"19","author":"Zhou","year":"2022","journal-title":"Cell Mol Immunol"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2015.03.007","article-title":"Regulation of human helper T cell subset differentiation by cytokines","volume":"34","author":"Schmitt","year":"2015","journal-title":"Curr Opin Immunol"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20150376","article-title":"IL-23 induced in keratinocytes by endogenous TLR4 ligands polarizes dendritic cells to drive IL-22 responses to skin immunization","volume":"213","author":"Yoon","year":"2016","journal-title":"J Exp Med"},{"key":"B105","doi-asserted-by":"publisher","first-page":"a028613","DOI":"10.1101\/cshperspect.a028613","article-title":"Development, diversity, and function of dendritic cells in mouse and human","volume":"10","author":"Anderson","year":"2018","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2018.00152","article-title":"Emerging roles of cellular metabolism in regulating dendritic cell subsets and function","volume":"6","author":"Du","year":"2018","journal-title":"Front Cell Dev Biol"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2014.00203","article-title":"Metabolic control of dendritic cell activation and function: recent advances and clinical implications","volume":"5","author":"Everts","year":"2014","journal-title":"Front Immunol"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.712313","article-title":"Novel therapeutic target(s) for psoriatic disease","volume":"9","author":"Thakur","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"B109","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.jdermsci.2009.01.003","article-title":"Increased expression of IL-12p70 and IL-23 by multiple dendritic cell and macrophage subsets in plaque psoriasis","volume":"54","author":"Yawalkar","year":"2009","journal-title":"J Dermatol Sci"},{"key":"B110","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.cyto.2019.02.018","article-title":"IL-23 and dendritic cells: What are the roles of their mutual attachment in immune response and immunotherapy","volume":"120","author":"Li","year":"2019","journal-title":"Cytokine"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.176.12.7768","article-title":"IL-23 is increased in dendritic cells in multiple sclerosis and down-regulation of IL-23 by antisense oligos increases dendritic cell IL-10 production","volume":"176","author":"Vaknin-Dembinsky","year":"2006","journal-title":"J Immunol"},{"key":"B112","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/s41419-023-05815-y","article-title":"TLR7-MyD88-DC-CXCL16 axis results neutrophil activation to elicit inflammatory response in pustular psoriasis","volume":"14","author":"Lu","year":"2023","journal-title":"Cell Death Dis"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-032713-120225","article-title":"Immunology of psoriasis","volume":"32","author":"Lowes","year":"2014","journal-title":"Annu Rev Immunol"},{"key":"B114","doi-asserted-by":"publisher","first-page":"112910","DOI":"10.1016\/j.celrep.2023.112910","article-title":"SLC38A5 aggravates DC-mediated psoriasiform skin inflammation via potentiating lysosomal acidification","volume":"42","author":"Zhu","year":"2023","journal-title":"Cell Rep"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2012.04.003","article-title":"Monocyte-derived interferon-alpha primed dendritic cells in the pathogenesis of psoriasis: new pieces in the puzzle","volume":"13","author":"Farkas","year":"2012","journal-title":"Int Immunopharmacol"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2193-0","article-title":"Bacterial metabolism of bile acids promotes generation of peripheral regulatory T cells","volume":"581","author":"Campbell","year":"2020","journal-title":"Nature"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.26429","article-title":"Macrophage plasticity, polarization, and function in health and disease","volume":"233","author":"Shapouri-Moghaddam","year":"2018","journal-title":"J Cell Physiol"},{"key":"B118","doi-asserted-by":"publisher","first-page":"155007","DOI":"10.1016\/j.phymed.2023.155007","article-title":"Characterization and active component identification of Premna herbacea roxb. root extract reveals anti-inflammatory effect and amelioration of imiquimod induced psoriasis via modulation of macrophage inflammatory response","volume":"119","author":"Sarkar","year":"2023","journal-title":"Phytomedicine"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1007\/s00441-017-2753-2","article-title":"Partners in crime: neutrophils and monocytes\/macrophages in inflammation and disease","volume":"371","author":"Prame Kumar","year":"2018","journal-title":"Cell Tissue Res"},{"key":"B120","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/j.jaci.2020.05.048","article-title":"Tape strips detect distinct immune and barrier profiles in atopic dermatitis and psoriasis","volume":"147","author":"He","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1038\/nri3088","article-title":"Transcriptional regulation of macrophage polarization: enabling diversity with identity","volume":"11","author":"Lawrence","year":"2011","journal-title":"Nat Rev Immunol"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2018.05.009","article-title":"Treatment with TNF-alpha inhibitor rectifies M1 macrophage polarization from blood CD14+ monocytes in patients with psoriasis independent of STAT1 and IRF-1 activation","volume":"91","author":"Lin","year":"2018","journal-title":"J Dermatol Sci"},{"key":"B123","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1038\/s41420-023-01575-y","article-title":"Selective activation of STAT3 and STAT5 dictates the fate of myeloid progenitor cells","volume":"9","author":"Zhang","year":"2023","journal-title":"Cell Death Discovery"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1093\/jleuko\/qiad088","article-title":"Recombinant GM-CSF enhances the bactericidal ability of PMNs by increasing intracellular IL-1beta and improves the prognosis of secondary Pseudomonas aeruginosa pneumonia in sepsis","volume":"114","author":"Tu","year":"2023","journal-title":"J Leukoc Biol"},{"key":"B125","doi-asserted-by":"publisher","first-page":"3523642","DOI":"10.1155\/2018\/3523642","article-title":"Involvement of M1 macrophage polarization in endosomal toll-like receptors activated psoriatic inflammation","volume":"2018","author":"Lu","year":"2018","journal-title":"Mediators Inflammation"},{"key":"B126","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1038\/s41420-023-01444-8","article-title":"Macrophages mediate psoriasis via Mincle-dependent mechanism in mice","volume":"9","author":"Tan","year":"2023","journal-title":"Cell Death Discovery"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1128543","article-title":"SIRT3 alleviates imiquimod-induced psoriatic dermatitis through deacetylation of XBP1s and modulation of TLR7\/8 inducing IL-23 production in macrophages","volume":"14","author":"Guo","year":"2023","journal-title":"Front Immunol"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2023.04.005","article-title":"Pseudomonas-dominant microbiome elicits sustained IL-1beta upregulation in alveolar macrophages from lung transplant recipients","volume":"42","author":"Britton","year":"2023","journal-title":"J Heart Lung Transplant"},{"key":"B129","doi-asserted-by":"publisher","first-page":"114469","DOI":"10.1016\/j.biopha.2023.114469","article-title":"The macrophage polarization in inflammatory dermatosis and its potential drug candidates","volume":"161","author":"Sun","year":"2023","journal-title":"BioMed Pharmacother"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02343","article-title":"Extracellular vesicles from the dermatophyte trichophyton interdigitale modulate macrophage and keratinocyte functions","volume":"9","author":"Bitencourt","year":"2018","journal-title":"Front Immunol"},{"key":"B131","doi-asserted-by":"publisher","first-page":"2210785","DOI":"10.1080\/10641963.2023.2210785","article-title":"Neutrophil and monocyte ratios to high-density lipoprotein cholesterol as biomarkers in non-dipping hypertension","volume":"45","author":"Zhang","year":"2023","journal-title":"Clin Exp Hypertens"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-021-00832-3","article-title":"Neutrophils in chronic inflammatory diseases","volume":"19","author":"Herrero-Cervera","year":"2022","journal-title":"Cell Mol Immunol"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2021.02.041","article-title":"Immunomodulatory aged neutrophils are augmented in blood and skin of psoriasis patients","volume":"148","author":"Rodriguez-Rosales","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"B134","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1038\/s41467-019-13756-4","article-title":"Neutrophil extracellular trap-associated RNA and LL37 enable self-amplifying inflammation in psoriasis","volume":"11","author":"Herster","year":"2020","journal-title":"Nat Commun"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-021-00655-y","article-title":"Pathophysiology of generalized pustular psoriasis","volume":"23","author":"Marrakchi","year":"2022","journal-title":"Am J Clin Dermatol"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01867","article-title":"Platelets aggregate with neutrophils and promote skin pathology in psoriasis","volume":"10","author":"Herster","year":"2019","journal-title":"Front Immunol"},{"key":"B137","doi-asserted-by":"publisher","first-page":"8567320","DOI":"10.1155\/2020\/8567320","article-title":"Targeting myeloid-derived suppressor cells is a novel strategy for anti-psoriasis therapy","volume":"2020","author":"Chen","year":"2020","journal-title":"Mediators Inflammation"},{"key":"B138","doi-asserted-by":"publisher","first-page":"110710","DOI":"10.1016\/j.intimp.2023.110710","article-title":"Targeting upregulation of the immunosuppressive activity of MDSCs with indirubin as a novel strategy to alleviate psoriasis","volume":"123","author":"Hou","year":"2023","journal-title":"Int Immunopharmacol"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2020.560579","article-title":"Polyethylene glycol ointment alleviates psoriasis-like inflammation through down-regulating the function of th17 cells and MDSCs","volume":"7","author":"Lu","year":"2020","journal-title":"Front Med (Lausanne)"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2021030426","article-title":"IL-17 receptor C signaling controls CD4(+) T(H)17 immune responses and tissue injury in immune-mediated kidney diseases","volume":"32","author":"Schmidt","year":"2021","journal-title":"J Am Soc Nephrol JASN"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61909-7","article-title":"Psoriasis","volume":"386","author":"Boehncke","year":"2015","journal-title":"Lancet"},{"key":"B142","doi-asserted-by":"publisher","first-page":"102614","DOI":"10.1016\/j.jaut.2021.102614","article-title":"Insights into interplay of immunopathophysiological events and molecular mechanistic cascades in psoriasis and its associated comorbidities","volume":"118","author":"Srivastava","year":"2021","journal-title":"J Autoimmun"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-103019-085803","article-title":"In vivo CD4(+) T cell differentiation and function: revisiting the th1\/th2 paradigm","volume":"38","author":"Ruterbusch","year":"2020","journal-title":"Annu Rev Immunol"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-021-00688-7","article-title":"New insights into follicular helper T cell response and regulation in autoimmune pathogenesis","volume":"18","author":"Xiao","year":"2021","journal-title":"Cell Mol Immunol"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1111\/1523-1747.ep12371679","article-title":"The cytokine network in lesional and lesion-free psoriatic skin is characterized by a T-helper type 1 cell-mediated response","volume":"101","author":"Uyemura","year":"1993","journal-title":"J Invest Dermatol"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1111\/1523-1747.ep12371752","article-title":"T cells involved in psoriasis vulgaris belong to the Th1 subset","volume":"102","author":"Schlaak","year":"1994","journal-title":"J Invest Dermatol"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2009.02.007","article-title":"Critical regulation of early Th17 cell differentiation by interleukin-1 signaling","volume":"30","author":"Chung","year":"2009","journal-title":"Immunity"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1038\/nri2295","article-title":"TH17 cells in development: an updated view of their molecular identity and genetic programming","volume":"8","author":"Dong","year":"2008","journal-title":"Nat Rev Immunol"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2015.2","article-title":"Immunologic overlap of helper T-cell subtypes 17 and 22 in erythrodermic psoriasis and atopic dermatitis","volume":"151","author":"Moy","year":"2015","journal-title":"JAMA Dermatol"},{"key":"B150","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1038\/s41419-019-2212-y","article-title":"Piperlongumine regulates epigenetic modulation and alleviates psoriasis-like skin inflammation via inhibition of hyperproliferation and inflammation","volume":"11","author":"Thatikonda","year":"2020","journal-title":"Cell Death Dis"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2012.11038.x","article-title":"A comparison of serum inflammatory cytokines according to phenotype in patients with psoriasis","volume":"167","author":"Choe","year":"2012","journal-title":"Br J Dermatol"},{"key":"B152","doi-asserted-by":"publisher","first-page":"4983","DOI":"10.3390\/ijms22094983","article-title":"Psoriasis: from pathogenesis to pharmacological and nano-technological-based therapeutics","volume":"22","author":"Petit","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B153","doi-asserted-by":"publisher","first-page":"7470","DOI":"10.1038\/s41467-023-43210-5","article-title":"Th17-associated cytokines IL-17 and IL-23 in inflamed skin of Darier disease patients as potential therapeutic targets","volume":"14","author":"Ettinger","year":"2023","journal-title":"Nat Commun"},{"key":"B154","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/s41392-023-01655-6","article-title":"Signaling pathways and targeted therapies for psoriasis","volume":"8","author":"Guo","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2012-302853","article-title":"Anti-TNF antibody-induced psoriasiform skin lesions in patients with inflammatory bowel disease are characterised by interferon-\u03b3-expressing Th1 cells and IL-17A\/IL-22-expressing Th17 cells and respond to anti-IL-12\/IL-23 antibody treatment","volume":"63","author":"Tillack","year":"2014","journal-title":"Gut"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.788940","article-title":"The role of helper T cells in psoriasis","volume":"12","author":"Hu","year":"2021","journal-title":"Front Immunol"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.1038\/nature05505","article-title":"Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis","volume":"445","author":"Zheng","year":"2007","journal-title":"Nature"},{"key":"B158","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s12016-017-8634-3","article-title":"Unmet needs in the field of psoriasis: pathogenesis and treatment","volume":"55","author":"Boehncke","year":"2018","journal-title":"Clin Rev Allergy Immunol"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2010.12.009","article-title":"Human slan (6-sulfo LacNAc) dendritic cells are inflammatory dermal dendritic cells in psoriasis and drive strong TH17\/TH1 T-cell responses","volume":"127","author":"H\u00e4nsel","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.1038\/nm1551","article-title":"A brief history of T(H)17, the first major revision in the T(H)1\/T(H)2 hypothesis of T cell-mediated tissue damage","volume":"13","author":"Steinman","year":"2007","journal-title":"Nat Med"},{"key":"B161","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.3390\/biom13071100","article-title":"Microbiota and IL-33\/31 axis linkage: implications and therapeutic perspectives in atopic dermatitis and psoriasis","volume":"13","author":"Bonzano","year":"2023","journal-title":"Biomolecules"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.745997","article-title":"Natural compounds tapinarof and galactomyces ferment filtrate downregulate IL-33 expression via the AHR\/IL-37 axis in human keratinocytes","volume":"13","author":"Tsuji","year":"2022","journal-title":"Front Immunol"},{"key":"B163","doi-asserted-by":"publisher","first-page":"372","DOI":"10.3390\/ijms24010372","article-title":"IL-33 and IL-37: A possible axis in skin and allergic diseases","volume":"24","author":"Borgia","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B164","doi-asserted-by":"publisher","first-page":"8076","DOI":"10.3390\/ijms22158076","article-title":"Mast cell cytokines IL-1, IL-33, and IL-36 mediate skin inflammation in psoriasis: A novel therapeutic approach with the anti-inflammatory cytokines IL-37, IL-38, and IL-1Ra","volume":"22","author":"Conti","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B165","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s12964-023-01075-7","article-title":"IL-33-mediated activation of mast cells is involved in the progression of imiquimod-induced psoriasis-like dermatitis","volume":"21","author":"Zhou","year":"2023","journal-title":"Cell Commun Signal"},{"key":"B166","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.jid.2020.07.027","article-title":"An autocrine circuit of IL-33 in keratinocytes is involved in the progression of psoriasis","volume":"141","author":"Zeng","year":"2021","journal-title":"J Invest Dermatol"},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.688066","article-title":"Role of th22 cells in the pathogenesis of autoimmune diseases","volume":"12","author":"Jiang","year":"2021","journal-title":"Front Immunol"},{"key":"B168","doi-asserted-by":"publisher","DOI":"10.1038\/cmi.2012.15","article-title":"New insights of T cells in the pathogenesis of psoriasis","volume":"9","author":"Cai","year":"2012","journal-title":"Cell Mol Immunol"},{"key":"B169","doi-asserted-by":"publisher","DOI":"10.1038\/ni.1770","article-title":"Identification of a human helper T cell population that has abundant production of interleukin 22 and is distinct from T(H)-17, T(H)1 and T(H)2 cells","volume":"10","author":"Trifari","year":"2009","journal-title":"Nat Immunol"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.1172\/JCI40202","article-title":"Th22 cells represent a distinct human T cell subset involved in epidermal immunity and remodeling","volume":"119","author":"Eyerich","year":"2009","journal-title":"J Clin Invest"},{"key":"B171","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaut.2017.12.007","article-title":"A cellular and molecular view of T helper 17 cell plasticity in autoimmunity","volume":"87","author":"Stadhouders","year":"2018","journal-title":"J Autoimmun"},{"key":"B172","doi-asserted-by":"publisher","DOI":"10.1038\/ni1261","article-title":"A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17","volume":"6","author":"Park","year":"2005","journal-title":"Nat Immunol"},{"key":"B173","doi-asserted-by":"publisher","first-page":"739","DOI":"10.3390\/ijms20030739","article-title":"Advances in understanding the immunological pathways in psoriasis","volume":"20","author":"Georgescu","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B174","doi-asserted-by":"publisher","first-page":"4348","DOI":"10.3390\/ijms24054348","article-title":"Autoreactive T-cells in psoriasis: are they spoiled tregs and can therapies restore their functions","volume":"24","author":"Pietraforte","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B175","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1111\/bjd.19380","article-title":"Role of regulatory T cells in psoriasis pathogenesis and treatment","volume":"184","author":"Nussbaum","year":"2021","journal-title":"Br J Dermatol"},{"key":"B176","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-214229","article-title":"Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trial","volume":"78","author":"Rosenzwajg","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"B177","doi-asserted-by":"publisher","DOI":"10.1038\/cmi.2010.22","article-title":"The cytokine milieu in the interplay of pathogenic Th1\/Th17 cells and regulatory T cells in autoimmune disease","volume":"7","author":"Leung","year":"2010","journal-title":"Cell Mol Immunol"},{"key":"B178","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01764","article-title":"Adaptive and innate immunity in psoriasis and other inflammatory disorders","volume":"10","author":"Sch\u00f6n","year":"2019","journal-title":"Front Immunol"},{"key":"B179","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2014.01.008","article-title":"Diagnosis and classification of psoriasis","volume":"13","author":"Raychaudhuri","year":"2014","journal-title":"Autoimmun Rev"},{"key":"B180","doi-asserted-by":"publisher","DOI":"10.1111\/1523-1747.ep12273499","article-title":"Subpopulations of mononuclear cells in microscopic lesions of psoriatic patients. Selective accumulation of suppressor\/cytotoxic T cells in epidermis during the evolution of the lesion","volume":"83","author":"Hammar","year":"1984","journal-title":"J Invest Dermatol"},{"key":"B181","doi-asserted-by":"publisher","DOI":"10.7150\/thno.45211","article-title":"Dihydroartemisinin ameliorates psoriatic skin inflammation and its relapse by diminishing CD8(+) T-cell memory in wild-type and humanized mice","volume":"10","author":"Chen","year":"2020","journal-title":"Theranostics"},{"key":"B182","doi-asserted-by":"publisher","DOI":"10.1007\/s00011-020-01320-6","article-title":"Tissue-resident memory T cells in the skin","volume":"69","author":"Khalil","year":"2020","journal-title":"Inflammation Res"},{"key":"B183","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-022-01229-8","article-title":"Tissue-resident memory CD8(+) T cells possess unique transcriptional, epigenetic and functional adaptations to different tissue environments","volume":"23","author":"Crowl","year":"2022","journal-title":"Nat Immunol"},{"key":"B184","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.immuni.2017.01.009","article-title":"CD49a expression defines tissue-resident CD8(+) T cells poised for cytotoxic function in human skin","volume":"46","author":"Cheuk","year":"2017","journal-title":"Immunity"},{"key":"B185","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00885","article-title":"Whodunit? The contribution of interleukin (IL)-17\/IL-22-producing \u03b3\u03b4 T cells, \u03b1\u03b2 T cells, and innate lymphoid cells to the pathogenesis of spondyloarthritis","volume":"9","author":"Reinhardt","year":"2018","journal-title":"Front Immunol"},{"key":"B186","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00242","article-title":"Innate lymphocytes in psoriasis","volume":"11","author":"Polese","year":"2020","journal-title":"Front Immunol"},{"key":"B187","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.immuni.2011.08.001","article-title":"Pivotal role of dermal IL-17-producing \u03b3\u03b4 T cells in skin inflammation","volume":"35","author":"Cai","year":"2011","journal-title":"Immunity"},{"key":"B188","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1111\/imr.12913","article-title":"\u03b3\u03b4 T cells and inflammatory skin diseases","volume":"298","author":"Jee","year":"2020","journal-title":"Immunol Rev"},{"key":"B189","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.635076","article-title":"Hyperforin ameliorates imiquimod-induced psoriasis-like murine skin inflammation by modulating IL-17A-producing \u03b3\u03b4 T cells","volume":"12","author":"Zhang","year":"2021","journal-title":"Front Immunol"},{"key":"B190","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.627139","article-title":"Gamma delta T cells and their pathogenic role in psoriasis","volume":"12","author":"Qi","year":"2021","journal-title":"Front Immunol"},{"key":"B191","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2009.06.020","article-title":"Interleukin-17-producing gammadelta T cells selectively expand in response to pathogen products and environmental signals","volume":"31","author":"Martin","year":"2009","journal-title":"Immunity"},{"key":"B192","doi-asserted-by":"publisher","first-page":"3034","DOI":"10.1016\/j.celrep.2019.05.019","article-title":"Differential roles of the mTOR-STAT3 signaling in dermal \u03b3\u03b4 T cell effector function in skin inflammation","volume":"27","author":"Cai","year":"2019","journal-title":"Cell Rep"},{"key":"B193","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1508990112","article-title":"Inflammation induces dermal V\u03b34+ \u03b3\u03b4T17 memory-like cells that travel to distant skin and accelerate secondary IL-17-driven responses","volume":"112","author":"Ram\u00edrez-Valle","year":"2015","journal-title":"Proc Natl Acad Sci United States America"},{"key":"B194","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1016\/j.jid.2021.11.004","article-title":"NF-\u03baB1 contributes to imiquimod-induced psoriasis-like skin inflammation by inducing V\u03b34(+)V\u03b44(+)\u03b3\u03b4T17 cells","volume":"142","author":"Suzuki","year":"2022","journal-title":"J Invest Dermatol"},{"key":"B195","doi-asserted-by":"publisher","DOI":"10.1007\/s10787-023-01257-2","article-title":"Emerging trends in combination strategies with phototherapy in advanced psoriasis management","volume":"31","author":"Sreya","year":"2023","journal-title":"Inflammopharmacology"},{"key":"B196","doi-asserted-by":"publisher","first-page":"388","DOI":"10.3390\/biom13020388","article-title":"Granzyme B in autoimmune skin disease","volume":"13","author":"Gleave","year":"2023","journal-title":"Biomolecules"},{"key":"B197","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.3390\/ijms19071906","article-title":"Roles of the glucocorticoid and mineralocorticoid receptors in skin pathophysiology","volume":"19","author":"Sevilla","year":"2018","journal-title":"Int J Mol Sci"},{"key":"B198","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2022.07.006","article-title":"Topical formulation based on disease-specific nanoparticles for single-dose cure of psoriasis","volume":"349","author":"Mai","year":"2022","journal-title":"J Control Release"},{"key":"B199","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2020.1757018","article-title":"Effect of narrow-band ultraviolet B phototherapy, methotrexate, and combined narrow-band ultraviolet B phototherapy with methotrexate on serum cathelicidin and vitamin D in patients with psoriasis vulgaris","volume":"33","author":"El-Hamd","year":"2022","journal-title":"J Dermatolog Treat"},{"key":"B200","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16357","article-title":"Localized inflammatory reactions at sites of subcutaneous methotrexate injections during treatment with ultraviolet B","volume":"179","author":"Muthiah","year":"2018","journal-title":"Br J Dermatol"},{"key":"B201","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1001\/jama.1970.03170310152060","article-title":"Methotrexate and psoriasis","volume":"213","author":"Hayes","year":"1970","journal-title":"JAMA"},{"key":"B202","doi-asserted-by":"publisher","first-page":"CD011535","DOI":"10.1002\/14651858.CD011535.pub5","article-title":"Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis","volume":"5","author":"Sbidian","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"key":"B203","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.02.019","article-title":"Risk of liver disease in patients with psoriasis, psoriatic arthritis, and rheumatoid arthritis receiving methotrexate: A population-based study","volume":"84","author":"Gelfand","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"B204","doi-asserted-by":"publisher","first-page":"CD011535","DOI":"10.1002\/14651858.CD011535.pub5","article-title":"Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis","volume":"5","author":"Sbidian","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"key":"B205","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2023.2184684","article-title":"Investigational systemic drugs for moderate to severe plaque psoriasis: What's new","volume":"32","author":"Calabrese","year":"2023","journal-title":"Expert Opin Investig Drugs"},{"key":"B206","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.iy.07.040189.003205","article-title":"The biology of cachectin\/TNF\u2013a primary mediator of the host response","volume":"7","author":"Beutler","year":"1989","journal-title":"Annu Rev Immunol"},{"key":"B207","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/0092-8674(95)90192-2","article-title":"The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor","volume":"83","author":"Grell","year":"1995","journal-title":"Cell"},{"key":"B208","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.4006","article-title":"Pathophysiology, clinical presentation, and treatment of psoriasis: A review","volume":"323","author":"Armstrong","year":"2020","journal-title":"JAMA"},{"key":"B209","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2017.00460","article-title":"Drugs for autoimmune inflammatory diseases: from small molecule compounds to anti-TNF biologics","volume":"8","author":"Li","year":"2017","journal-title":"Front Pharmacol"},{"key":"B210","doi-asserted-by":"publisher","DOI":"10.1084\/jem.181.2.607","article-title":"Monoclonal antibodies specific for murine p55 and p75 tumor necrosis factor receptors: identification of a novel in vivo role for p75","volume":"181","author":"Sheehan","year":"1995","journal-title":"J Exp Med"},{"key":"B211","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-017-0246-1","article-title":"GP2015: an etanercept biosimilar","volume":"31","author":"Deeks","year":"2017","journal-title":"BioDrugs"},{"key":"B212","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.11.057","article-title":"Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics","volume":"80","author":"Menter","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"B213","doi-asserted-by":"publisher","DOI":"10.1016\/j.tibtech.2018.05.002","article-title":"Infliximab biosimilars in the age of personalized medicine","volume":"36","author":"Kang","year":"2018","journal-title":"Trends Biotechnol"},{"key":"B214","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.638444","article-title":"Efficacy and safety of adalimumab biosimilars: current critical clinical data in rheumatoid arthritis","volume":"12","author":"Lu","year":"2021","journal-title":"Front Immunol"},{"key":"B215","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-021-10793-2","article-title":"Adalimumab for CNS sarcoidosis: single-center experience and literature review","volume":"269","author":"Hutto","year":"2022","journal-title":"J Neurol"},{"key":"B216","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-020-00416-z","article-title":"Certolizumab pegol: A review in moderate to severe plaque psoriasis","volume":"34","author":"Lee","year":"2020","journal-title":"BioDrugs"},{"key":"B217","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2019.1566456","article-title":"Etanercept biosimilar SB-4","volume":"19","author":"Pelechas","year":"2019","journal-title":"Expert Opin Biol Ther"},{"key":"B218","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2013.78","article-title":"Which antipsoriatic drug has the fastest onset of action? Systematic review on the rapidity of the onset of action","volume":"133","author":"Nast","year":"2013","journal-title":"J Invest Dermatol"},{"key":"B219","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.14867","article-title":"A prospective randomized controlled trial comparing infliximab and etanercept in patients with moderate-to-severe chronic plaque-type psoriasis: the Psoriasis Infliximab vs. Etanercept Comparison Evaluation (PIECE) study","volume":"176","author":"de Vries","year":"2017","journal-title":"Br J Dermatol"},{"key":"B220","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-015-0503-x","article-title":"Adalimumab: A review in chronic plaque psoriasis","volume":"75","author":"Burness","year":"2015","journal-title":"Drugs"},{"key":"B221","doi-asserted-by":"publisher","DOI":"10.1177\/0091270009339192","article-title":"Population pharmacokinetics of golimumab, an anti-tumor necrosis factor-alpha human monoclonal antibody, in patients with psoriatic arthritis","volume":"49","author":"Xu","year":"2009","journal-title":"J Clin Pharmacol"},{"key":"B222","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.12304","article-title":"Characterization of golimumab, a human monoclonal antibody specific for human tumor necrosis factor alpha","volume":"2","author":"Shealy","year":"2010","journal-title":"MAbs"},{"key":"B223","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(08)70227-5","article-title":"Tumour necrosis factor antagonists: structure, function, and tuberculosis risks","volume":"8","author":"Wallis","year":"2008","journal-title":"Lancet Infect Dis"},{"key":"B224","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3229","article-title":"Development trends for human monoclonal antibody therapeutics, Nature reviews","volume":"9","author":"Nelson","year":"2010","journal-title":"Drug Discovery"},{"key":"B225","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2019.04.029","article-title":"IL-17A inhibition by secukinumab induces early clinical, histopathologic, and molecular resolution of psoriasis","volume":"144","author":"Krueger","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"B226","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2020.1729736","article-title":"Ixekizumab for the treatment of psoriasis: up-to-date","volume":"20","author":"Craig","year":"2020","journal-title":"Expert Opin Biol Ther"},{"key":"B227","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s40265-018-0888-4","article-title":"Brodalumab: A review in moderate to severe plaque psoriasis","volume":"78","author":"Blair","year":"2018","journal-title":"Drugs"},{"key":"B228","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211555","article-title":"Novel therapies for immune-mediated inflammatory diseases: What can we learn from their use in rheumatoid arthritis, spondyloarthritis, systemic lupus erythematosus, psoriasis, Crohn's disease and ulcerative colitis","volume":"77","author":"Baker","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"B229","doi-asserted-by":"publisher","DOI":"10.2147\/CCID.S165605","article-title":"Spotlight on brodalumab in the treatment of plaque psoriasis: the evidence to date","volume":"12","author":"Galluzzo","year":"2019","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"B230","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217159","article-title":"EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update","volume":"79","author":"Gossec","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"B231","doi-asserted-by":"publisher","DOI":"10.1002\/art.39573","article-title":"Group for research and assessment of psoriasis and psoriatic arthritis 2015 treatment recommendations for psoriatic arthritis","volume":"68","author":"Coates","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"B232","doi-asserted-by":"publisher","first-page":"e14486","DOI":"10.1111\/dth.14486","article-title":"Ixekizumab in the treatment of moderate-to-severe plaque psoriasis: Patient adherence, satisfaction, and preferences","volume":"34","author":"Azhar","year":"2021","journal-title":"Dermatol Ther"},{"key":"B233","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.11.015","article-title":"Comparison of real-world treatment patterns among patients with psoriasis prescribed ixekizumab or secukinumab","volume":"82","author":"Blauvelt","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"B234","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01894","article-title":"Bimekizumab, a novel humanized igG1 antibody that neutralizes both IL-17A and IL-17F","volume":"11","author":"Adams","year":"2020","journal-title":"Front Immunol"},{"key":"B235","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.jaad.2018.03.037","article-title":"Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: Results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial","volume":"79","author":"Papp","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"B236","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215356","article-title":"The role of IL-17A in axial spondyloarthritis and psoriatic arthritis: recent advances and controversies","volume":"78","author":"McGonagle","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"B237","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-220865","article-title":"Treating the skin with biologics in patients with psoriasis decreases the incidence of psoriatic arthritis","volume":"81","author":"Acosta Felquer","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"B238","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-023-00768-1","article-title":"IL-12 and IL-23 pathway inhibition in inflammatory bowel disease","volume":"20","author":"Verstockt","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B239","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)31773-8","article-title":"Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial","volume":"394","author":"Reich","year":"2019","journal-title":"Lancet"},{"key":"B240","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19509","article-title":"A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 24-week efficacy and safety results from a randomized, double-blinded trial","volume":"184","author":"Blauvelt","year":"2021","journal-title":"Br J Dermatol"},{"key":"B241","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30265-8","article-title":"Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFalpha inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial","volume":"395","author":"Deodhar","year":"2020","journal-title":"Lancet"},{"key":"B242","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30263-4","article-title":"Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial","volume":"395","author":"Mease","year":"2020","journal-title":"Lancet"},{"key":"B243","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2022.2909","article-title":"Drug survival associated with effectiveness and safety of treatment with guselkumab, ixekizumab, secukinumab, ustekinumab, and adalimumab in patients with psoriasis","volume":"158","author":"Yiu","year":"2022","journal-title":"JAMA Dermatol"},{"key":"B244","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15750","article-title":"Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double-blind, phase III NAVIGATE trial","volume":"178","author":"Langley","year":"2018","journal-title":"Br J Dermatol"},{"key":"B245","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30265-8","article-title":"Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNF\u03b1 inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial","volume":"395","author":"Deodhar","year":"2020","journal-title":"Lancet"},{"key":"B246","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31279-5","article-title":"Tildrakizumab versus placebo or etanercept for chronic plaque psoriasis (reSURFACE 1 and reSURFACE 2): results from two randomised controlled","volume":"390","author":"Reich","year":"2017","journal-title":"phase 3 trials Lancet"},{"key":"B247","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-219014","article-title":"Efficacy and safety of tildrakizumab in patients with active psoriatic arthritis: results of a randomised, double-blind, placebo-controlled, multiple-dose, 52-week phase IIb study","volume":"80","author":"Mease","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"B248","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.21743","article-title":"Efficacy and safety of mirikizumab in psoriasis: results from a 52-week, double-blind, placebo-controlled, randomized withdrawal, phase III trial (OASIS-1)","volume":"187","author":"Blauvelt","year":"2022","journal-title":"Br J Dermatol"},{"key":"B249","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.01.025","article-title":"Guselkumab and risankizumab for psoriasis: a 44-week indirect real-life comparison","volume":"85","author":"Ruggiero","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"B250","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-213328","article-title":"Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study","volume":"77","author":"Baeten","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"B251","doi-asserted-by":"publisher","DOI":"10.26508\/lsa.202000688","article-title":"IL-36 signaling in keratinocytes controls early IL-23 production in psoriasis-like dermatitis","volume":"3","author":"Goldstein","year":"2020","journal-title":"Life Sci Alliance"},{"key":"B252","doi-asserted-by":"publisher","first-page":"3455","DOI":"10.1038\/s41467-023-39020-4","article-title":"Single cell and spatial sequencing define processes by which keratinocytes and fibroblasts amplify inflammatory responses in psoriasis","volume":"14","author":"Ma","year":"2023","journal-title":"Nat Commun"},{"key":"B253","doi-asserted-by":"publisher","DOI":"10.1093\/bjd\/ljad083","article-title":"Imsidolimab, an anti-interleukin-36 receptor monoclonal antibody, for the treatment of generalized pustular psoriasis: results from the phase II GALLOP trial","volume":"189","author":"Warren","year":"2023","journal-title":"Br J Dermatol"},{"key":"B254","doi-asserted-by":"publisher","first-page":"3318","DOI":"10.3390\/ijms20133318","article-title":"The significance of IL-36 hyperactivation and IL-36R targeting in psoriasis","volume":"20","author":"Madonna","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B255","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2017.12.024","article-title":"Unopposed IL-36 activity promotes clonal CD4(+) T-cell responses with IL-17A production in generalized pustular psoriasis","volume":"138","author":"Arakawa","year":"2018","journal-title":"J Invest Dermatol"},{"key":"B256","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.jaad.2023.02.040","article-title":"Rapid and sustained improvements in Generalized Pustular Psoriasis Physician Global Assessment scores with spesolimab for treatment of generalized pustular psoriasis flares in the randomized, placebo-controlled Effisayil 1 study","volume":"89","author":"Elewski","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"B257","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2021.11.009","article-title":"Pustular psoriasis as an autoinflammatory keratinization disease (AiKD): Genetic predisposing factors and promising therapeutic targets","volume":"105","author":"Akiyama","year":"2022","journal-title":"J Dermatol Sci"},{"key":"B258","doi-asserted-by":"publisher","DOI":"10.1016\/j.cytogfr.2020.06.006","article-title":"IL-36 in chronic inflammation and cancer","volume":"55","author":"Neurath","year":"2020","journal-title":"Cytokine Growth Factor Rev"},{"key":"B259","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2018.06.136","article-title":"Emerging landscape in psoriasis management: From topical application to targeting biomolecules","volume":"106","author":"Rapalli","year":"2018","journal-title":"BioMed Pharmacother"},{"key":"B260","doi-asserted-by":"publisher","first-page":"103465","DOI":"10.1016\/j.drudis.2022.103465","article-title":"Insight into the pivotal role of signaling pathways in psoriasis pathogenesis, potential therapeutic molecules and drug delivery approaches","volume":"28","author":"Tomar","year":"2023","journal-title":"Drug Discovery Today"},{"key":"B261","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1021537","article-title":"Efficacy and safety profile of phosphodiesterase 4 inhibitor in the treatment of psoriasis: A systematic review and meta-analysis of randomized controlled trials","volume":"13","author":"Kang","year":"2022","journal-title":"Front Immunol"},{"key":"B262","doi-asserted-by":"publisher","first-page":"adv00545","DOI":"10.2340\/00015555-3846","article-title":"Effectiveness of apremilast in real life in patients with psoriasis: A longitudinal study","volume":"101","author":"Malara","year":"2021","journal-title":"Acta dermato-venereologica"},{"key":"B263","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.10.009","article-title":"Apremilast and psoriasis in the real world: A retrospective case series","volume":"83","author":"Dozier","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"B264","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.jaad.2021.07.040","article-title":"Efficacy and safety of apremilast in patients with mild-to-moderate plaque psoriasis: Results of a phase 3, multicenter, randomized, double-blind, placebo-controlled trial","volume":"86","author":"Stein Gold","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"B265","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1038\/nrd4017","article-title":"Trial watch: PDE4 inhibitor leads wave of target-specific oral psoriasis drugs, Nature reviews","volume":"12","author":"Harrison","year":"2013","journal-title":"Drug Discovery"},{"key":"B266","doi-asserted-by":"publisher","DOI":"10.1096\/fj.201800354","article-title":"Topical application of anthranilate derivatives ameliorates psoriatic inflammation in a mouse model by inhibiting keratinocyte-derived chemokine expression and neutrophil infiltration","volume":"32","author":"Lin","year":"2018","journal-title":"FASEB J"},{"key":"B267","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.17769","article-title":"Apremilast effectively inhibits TNF\u03b1-induced vascular inflammation in human endothelial cells","volume":"36","author":"Otto","year":"2022","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B268","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.625130","article-title":"Acitretin promotes the differentiation of myeloid-derived suppressor cells in the treatment of psoriasis","volume":"8","author":"Liu","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"B269","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.15632","article-title":"Effect of roflumilast cream vs vehicle cream on chronic plaque psoriasis: the DERMIS-1 and DERMIS-2 randomized clinical trials","volume":"328","author":"Lebwohl","year":"2022","journal-title":"Jama"},{"key":"B270","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-020-01261-8","article-title":"JAK inhibitors for treatment of psoriasis: focus on selective TYK2 inhibitors","volume":"80","author":"Nogueira","year":"2020","journal-title":"Drugs"},{"key":"B271","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.8b00588","article-title":"Combating autoimmune diseases with retinoic acid receptor-related orphan receptor-gamma (RORgamma or RORc) inhibitors: hits and misses","volume":"61","author":"Pandya","year":"2018","journal-title":"J Med Chem"},{"key":"B272","doi-asserted-by":"publisher","DOI":"10.1080\/17460441.2021.1948833","article-title":"Retinoic acid-related orphan receptor gamma t (RORgammat) inverse agonists\/antagonists for the treatment of inflammatory diseases - where are we presently","volume":"16","author":"Gege","year":"2021","journal-title":"Expert Opin Drug Discovery"},{"key":"B273","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.06.869","article-title":"Tyrosine kinase 2 and Janus kinase\u2012signal transducer and activator of transcription signaling and inhibition in plaque psoriasis","volume":"86","author":"Krueger","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"B274","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-022-01796-y","article-title":"Deucravacitinib: first approval","volume":"82","author":"Hoy","year":"2022","journal-title":"Drugs"},{"key":"B275","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.2c01800","article-title":"Development and therapeutic implications of tyrosine kinase 2 inhibitors","volume":"66","author":"Zhang","year":"2023","journal-title":"J Med Chem"},{"key":"B276","doi-asserted-by":"publisher","DOI":"10.1152\/physrev.00049.2017","article-title":"Pharmacology of adenosine receptors: the state of the art","volume":"98","author":"Borea","year":"2018","journal-title":"Physiol Rev"},{"key":"B277","doi-asserted-by":"publisher","DOI":"10.1002\/med.21456","article-title":"A(3) adenosine receptors as modulators of inflammation: from medicinal chemistry to therapy","volume":"38","author":"Jacobson","year":"2018","journal-title":"Med Res Rev"},{"key":"B278","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1007\/s40257-016-0179-3","article-title":"Novel oral therapies for psoriasis and psoriatic arthritis","volume":"17","author":"Yiu","year":"2016","journal-title":"Am J Clin Dermatol"},{"key":"B279","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2020.04.004","article-title":"Metabolic pathways that control skin homeostasis and inflammation","volume":"26","author":"Cibrian","year":"2020","journal-title":"Trends Mol Med"},{"key":"B280","doi-asserted-by":"publisher","first-page":"102916","DOI":"10.1016\/j.jaut.2022.102916","article-title":"Pathogenesis, multi-omics research, and clinical treatment of psoriasis","volume":"133","author":"Yu","year":"2022","journal-title":"J Autoimmun"},{"key":"B281","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.3390\/ijms23031693","article-title":"Predominant role of mTOR signaling in skin diseases with therapeutic potential","volume":"23","author":"Karagianni","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B282","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02786","article-title":"Epidermal mTORC1 signaling contributes to the pathogenesis of psoriasis and could serve as a therapeutic target","volume":"9","author":"Buerger","year":"2018","journal-title":"Front Immunol"},{"key":"B283","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.15040920","article-title":"Long-term immunosuppression management: opportunities and uncertainties","volume":"16","author":"Wojciechowski","year":"2021","journal-title":"Clin J Am Soc Nephrol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1340677\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,4]],"date-time":"2024-01-04T05:06:37Z","timestamp":1704344797000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1340677\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,4]]},"references-count":283,"alternative-id":["10.3389\/fimmu.2023.1340677"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1340677","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,4]]},"article-number":"1340677"}}